NCT06429761View on ClinicalTrials.gov

Phase 4 Study to Assess the Safety of Trastuzumab Deruxtecan, in Indian Patients

PHASE4RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

January 2, 2025

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2026

Conditions
BREAST CANCER
Interventions
DRUG

Trastuzumab deruxtecan

IV infusion Trastuzumab deruxtecan will be administered at 5.4 mg/kg on day 1 of a 21 day cycle for 9 cycles.

Trial Locations (4)

221005

RECRUITING

Research Site, Varanasi

411028

RECRUITING

Research Site, Pune

560017

RECRUITING

Research Site, Bangalore

682041

RECRUITING

Research Site, Kochi

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY